Breaking News
5491 - 5505 of 6623 results
Prev
365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442
Next
July 10, 2007
Roche's Phase III Actemra RADIATE (RheumAtoiD ArthritIs Study in Anti-TNF FailurEs) trial met its primary endpoint in patients with moderate to severe rheumatoid arthritis (RA) who failed to respond to anti-tumor necrosis factor treatments (anti-TNFs…
Read More »
July 10, 2007
Vincent Lagrotteria has been appointed vice president, global sales and marketing, Bilcare. Mr. Lagrotteria has more than 20 years of healthcare industry experience in global sales, marketing, business, process improvement and corporate development.…
Read More »
July 9, 2007
Roche and Alnylam Pharmaceuticals have entered into a major alliance in which Roche will obtain a non-exclusive license to Alnylam's RNAi technology platform. The alliance will initially cover four therapeutic areas: oncology, respiratory diseases, m…
Read More »
July 9, 2007
Novavax, Inc. signed a non-exclusive, worldwide license agreement with Wyeth for the rights to a patent application covering virus-like particle (VLP) technology for vaccines. The agreement includes an upfront payment, annual license fees, milestone…
Read More »
July 9, 2007
InterMune, Inc. has entered into a new supply agreement with Boehringer Ingelheim Austria GmbH for Actimmune, eliminating InterMune's $91.6 million in future purchase commitments that existed under the previous supply agreement. InterMune will pay BI…
Read More »
July 6, 2007
Quintiles Transnational Corp. has announced plans to expand and consolidate its Global Central Laboratories (GCL) in Smyrna, GA, and its Clinical Development Services (CDS) office in Atlanta within a single structure in nearby Marietta, GA.
The 20…
Read More »
July 6, 2007
AstraZeneca has entered an R&D pact with Silence Therapeutics in the respiratory field. Silence will receive initial access fees, clinical development and commercial milestone payments as much as $400 million, plus royalties on product sales.…
Read More »
July 6, 2007
Bristol-Myers Squibb has cancelled development of Medivir's preclinical HIV compound MIV-170. The compound did not meet the BMS's desired profile, according to a Medivir statement. MIV-170 belongs to the group of polymerase inhibitors that Medivir al…
Read More »
July 5, 2007
DSM subsidiary DSM Nutritional Products Ltd. has acquired privately owned Pentapharm Holding Ltd. Pentapharm is a developer and producer of active ingredients and system solutions for the cosmetics industry but also has a presence in pharmaceutical a…
Read More »
July 3, 2007
Novartis and Intercell AG have formed a strategic alliance for the development of vaccines. The alliance combines Novartis' research, development, manufacturing and commercialization capabilities with Intercell's research skills and pipeline.
I…
Read More »
July 3, 2007
Roche received approval from the FDA for its sNDA to market Tamiflu capsules in 30 mg and 45 mg doses. The lower dose capsules provide an alternative for the treatment and prevention of influenza types A and B in patients one year and older. The caps…
Read More »
July 3, 2007
Novartis Vaccines will increase the supply of its Fluvirin vaccine 30% for distribution in the U.S. during the 2007-2008 flu season and plans to produce approximately 40 million doses. Based on accelerated production plans, half of these doses are pl…
Read More »
July 2, 2007
Biogen Idec and Cardiokine, Inc. have signed an agreement to jointly develop lixivaptan, an oral compound expected to enter a Phase III trial this year for the treatment of hyponatremia in patients with congestive heart failure (CHF).
Lixivaptan…
Read More »
July 2, 2007
Abraxis BioScience, Inc. has plans to split its hospital-based product business, Abraxis Pharmaceutical Products (APP) and Abraxis Oncology and Abraxis Research (the new Abraxis BioScience), into two independent, public companies. According to the co…
Read More »
July 2, 2007
Sanofi-Aventis is withdrawing its application for rimonabant for the treatment of obesity in the U.S. A U.S. advisory panel recently said that the drug should not be approved because it may increase suicidal thoughts and depression.
The company…
Read More »
5491 - 5505 of 6623 results
Prev
365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442
Next
